Update: Report: Abbott prescription med unit could bring $54B

Yesterday's announcement of Abbott Laboratories' ($ABT) split into two companies has prompted speculation over whether the prescription-medicine spin-off could become a takeover target. Some analysts are saying that the company could fetch as much as $54 billion. Jeffrey Holford, a Jefferies Group analyst, names Merck ($MRK), Roche and Bayer as potential interested parties. News

Editor's Note: The headline for this story was updated and corrected to change the potential sum of a buyout of Abbott's prescription medicine business from $54 million to $54 billion.

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.